[en] Several clinical reports indicate that the use of amphetaminic anorectic drugs or ergot derivatives could cause valvular heart disease (VHD). We sought to investigate whether valvular lesions develop in response to long-term oral administration of these drugs and to identify drug-targeted biological processes that may lead to VHD. Treatment of New Zealand White rabbits with pergolide, dexfenfluramine, or high-dose serotonin for 16 weeks induced valvular alterations characterized by extracellular matrix remodeling. Transcriptome profiling of tricuspid valves using RNA sequencing revealed distinct patterns of differentially expressed genes (DEGs) that clustered according to the different treatments. Genes that were affected by the three treatments were functionally enriched for reduced cell metabolism processes. The two drugs yielded more changes in gene expression than serotonin and shared most of the DEGs. These DEGs were mostly enriched for decreased biosynthetic processes, increased cell-matrix interaction, and cell response to growth factors, including TGF-β, which was associated with p38 MAPK activation. Treatment with pergolide specifically affected genes involved in homeostasis, which was corroborated by the activation of the master regulator of cell energy homeostasis, AMPK-α, as well as decreased levels of metabolism-related miR-107. Thus, both pergolide and dexfenfluramine may cause VHD through valve metabolic reprogramming and matrix remodeling.
Lancellotti, P.; Nchimi, A.; Hego, A.; Dulgheru, R.; Delvenne, P.; Drion, P.; Oury, C. High-dose oral intake of serotonin induces valvular heart disease in rabbits. Int. J. Cardiol. 2015, 197, 72–75.
Droogmans, S.; Roosens, B.; Cosyns, B.; Degaillier, C.; Hernot, S.; Weytjens, C.; Garbar, C.; Caveliers, V.; Pipeleers-Marichal, M.; Franken, P.R.; et al. Cyproheptadine prevents pergolide-induced valvulopathy in rats: An echocardiographic and histopathological study. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H1940– H1948.
Ayme-Dietrich, E.; Lawson, R.; Cote, F.; de Tapia, C.; Da Silva, S.; Ebel, C.; Hechler, B.; Gachet, C.; Guyonnet, J.; Rouillard, H.; et al. The role of 5-ht2b receptors in mitral valvulopathy: Bone marrow mobilization of endothelial progenitors. Br. J. Pharm. 2017, 174, 4123–4139.
Rothman, R.B.; Baumann, M.H.; Savage, J.E.; Rauser, L.; McBride, A.; Hufeisen, S.J.; Roth, B.L. Evidence for possible involvement of 5-ht(2b) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102, 2836–2841.
McDonald, P.C.; Wilson, J.E.; Gao, M.; McNeill, S.; Spinelli, J.J.; Williams, O.D.; Harji, S.; Kenyon, J.; McManus, B.M. Quantitative analysis of human heart valves: Does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol. 2002, 11, 251–262.
Rabkin, E.; Aikawa, M.; Stone, J.R.; Fukumoto, Y.; Libby, P.; Schoen, F.J. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001, 104, 2525–2532.
Wang, H.; Leinwand, L.A.; Anseth, K.S. Cardiac valve cells and their microenvironment--insights from in vitro studies. Nat. Rev. Cardiol. 2014, 11, 715–727.
Grande-Allen, K. Fibrotic vs. Myxomatous remodeling of mitral valves. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2004, 2004, 3737–3740.
Liu, A.C.; Gotlieb, A.I. Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells. Am. J. Pathol. 2008, 173, 1275–1285.
Mathieu, P.; Despres, J.P.; Pibarot, P. The 'valvulo-metabolic' risk in calcific aortic valve disease. Can. J. Cardiol. 2007, 23 (Suppl. B), 32B–39B.
Drolet, M.C.; Roussel, E.; Deshaies, Y.; Couet, J.; Arsenault, M. A high fat/high carbohydrate diet induces aortic valve disease in c57bl/6j mice. J. Am. Coll. Cardiol. 2006, 47, 850–855.
Kamel, P.I.; Qu, X.; Geiszler, A.M.; Nagrath, D.; Harmancey, R.; Taegtmeyer, H.; Grande-Allen, K.J. Metabolic regulation of collagen gel contraction by porcine aortic valvular interstitial cells. J. R. Soc. Interface 2014, 11, 20140852.
Yip, C.Y.; Chen, J.H.; Zhao, R.; Simmons, C.A. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arter. Thromb. Vasc. Biol. 2009, 29, 936–942.
Sunyer, R.; Ritort, F.; Farre, R.; Navajas, D. Thermal activation and atp dependence of the cytoskeleton remodeling dynamics. Phys. Review. Estat. Nonlinearand Soft Matter Phys. 2009, 79, 051920.
Kyndt, F.; Gueffet, J.P.; Probst, V.; Jaafar, P.; Legendre, A.; Le Bouffant, F.; Toquet, C.; Roy, E.; McGregor, L.; Lynch, S.A.; et al. Mutations in the gene encoding filamin a as a cause for familial cardiac valvular dystrophy. Circulation 2007, 115, 40–49.
Durst, R.; Sauls, K.; Peal, D.S.; de Vlaming, A.; Toomer, K.; Leyne, M.; Salani, M.; Talkowski, M.E.; Brand, H.; Perrocheau, M.; et al. Mutations in dchs1 cause mitral valve prolapse. Nature 2015, 525, 109–113.
Lam, N.T.; Muldoon, T.J.; Quinn, K.P.; Rajaram, N.; Balachandran, K. Valve interstitial cell contractile strength and metabolic state are dependent on its shape. Integr. Biol. Quant. Biosci. Nano Macro 2016, 8, 1079– 1089.
Hardie, D.G.; Schaffer, B.E.; Brunet, A. Ampk: An energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol. 2016, 26, 190–201.
Day, E.A.; Ford, R.J.; Steinberg, G.R. Ampk as a therapeutic target for treating metabolic diseases. Trends Endocrinol. Metab. 2017, 28, 545–560.
Trajkovski, M.; Hausser, J.; Soutschek, J.; Bhat, B.; Akin, A.; Zavolan, M.; Heim, M.H.; Stoffel, M. Micrornas 103 and 107 regulate insulin sensitivity. Nature 2011, 474, 649–653.
Padang, R.; Bagnall, R.D.; Tsoutsman, T.; Bannon, P.G.; Semsarian, C. Comparative transcriptome profiling in human bicuspid aortic valve disease using RNA sequencing. Physiol. Genom. 2015, 47, 75–87.
Guauque-Olarte, S.; Droit, A.; Tremblay-Marchand, J.; Gaudreault, N.; Kalavrouziotis, D.; Dagenais, F.; Seidman, J.G.; Body, S.C.; Pibarot, P.; Mathieu, P.; et al. RNA expression profile of calcified bicuspid, tricuspid, and normal human aortic valves by RNA sequencing. Physiol. Genom. 2016, 48, 749–761.
Kim, D.; Pertea, G.; Trapnell, C.; Pimentel, H.; Kelley, R.; Salzberg, S.L. Tophat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013, 14, R36.
Anders, S.; Pyl, P.T.; Huber, W. Htseq--a python framework to work with high-throughput sequencing data. Bioinformatics 2015, 31, 166–169.
Bourgon, R.; Gentleman, R.; Huber, W. Independent filtering increases detection power for high-throughput experiments. Proc. Natl. Acad. Sci. USA 2010, 107, 9546–9551.
Risso, D.; Ngai, J.; Speed, T.P.; Dudoit, S. Normalization of rna-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 2014, 32, 896–902.